title: Neutralizing antibodies to interferon (IFN) alpha-2a and IFN beta-1a or IFN beta-1b in MS are not cross-reactive.
abstract: Sera from patients with MS treated with recombinant interferon (rIFN) alpha-2a, rIFNbeta-1a, or rIFNbeta-1b were analyzed for cross-reacting neutralizing antibodies (NAB). Because cross-reactivity was not found, switching treatment from rIFNbeta-1a or rIFNbeta-1b to rIFNalpha-2a might provide a secondary treatment response in patients with NAB to rIFNbeta-1a or rIFNbeta-1b. A positive treatment response also might be achieved by switching NAB rIFNalpha-2a-positive patients to rIFNbeta-1a or rIFNbeta-1b.
authors.affiliation: Department of Neurology, Haukeland University Hospital, University of Bergen, Norway. Kjell.M.Myhr@nevro.haukeland.no
authors.forename: K M
authors.initials: KM
authors.lastname: Myhr
authors.forename: C
authors.initials: C
authors.lastname: Ross
authors.forename: H I
authors.initials: HI
authors.lastname: Nyland
authors.forename: K
authors.initials: K
authors.lastname: Bendtzen
authors.forename: C A
authors.initials: CA
authors.lastname: Vedeler
mesh_terms: D000328:Adult; D000906:Antibodies / Q000276:immunology*; D005260:Female; D006801:Humans; D000077190:Interferon alpha-2; D000068556:Interferon beta-1a; D000068576:Interferon beta-1b; D016898:Interferon-alpha / Q000276:immunology*; D016899:Interferon-beta / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000276:immunology*; D011994:Recombinant Proteins
chemical_list: D000906:Antibodies; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D000068576:Interferon beta-1b; D016899:Interferon-beta; D000068556:Interferon beta-1a